Serina Therapeutics
Serina Therapeutics, Inc. is a clinical-stage pharmaceutical company based in Huntsville, Alabama, focused on developing novel therapeutics for neurological diseases, cancer, pain, and metabolic disorders. Founded in 2006, the company utilizes its proprietary polymer technology, specifically polyoxazoline (POZ), to create new drug candidates. This technology allows for the attachment of small molecules, proteins, peptides, and DNA to the polymers, resulting in enhanced pharmacokinetic profiles that can improve safety and efficacy compared to the parent compounds. Serina's pipeline includes drug candidates aimed at treating conditions such as Parkinson’s disease, refractory epilepsy, post-operative pain, and chemotherapy-induced nausea and vomiting. The company's innovative POZ platform is designed to provide precise control over drug loading and release rates, addressing the limitations of traditional biocompatible polymers.
AgeX Therapeutics
Acquisition in 2024
AgeX Therapeutics is a biotechnology company dedicated to developing innovative therapeutics aimed at addressing human aging and degenerative diseases. Based in Alameda, California, the company focuses on harnessing proprietary technologies, such as telomerase-mediated cell immortality and induced Tissue Regeneration (iTR), to create treatments for age-related conditions. Its primary product pipeline includes two cell-based therapies: AGEX-BAT1, designed to treat age-related metabolic disorders like Type II diabetes, and AGEX-VASC1, which aims to restore vascular support in ischemic tissues. Additionally, AgeX is advancing AGEX-iTR1547, a drug-based formulation intended to enhance regenerative potential in aged tissues affected by degenerative diseases. The company also markets human embryonic stem cells and offers tools for genomic interpretation through the GeneCards Database Suite. AgeX Therapeutics collaborates with academic institutions, including a research program with the University of California, Irvine, focusing on neural stem cells for Huntington's disease and other neurological disorders. Founded in 2017, AgeX continues to explore novel solutions for aging-related challenges.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.